K. OGASAWARA
Researcher Next ID · RN-034523
Researcher · Biochemistry, Genetics and Molecular Biology
Bristol-Myers Squibb (United States)
New York, Sweden
- Works count
- 558
- Citation count
- 10,120
- H-index
- 45
- i10-index
- 123
Research interests
Publications
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00662-6
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
Blood · 2022 · https://doi.org/10.1182/blood.2022018730
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)31366-0
Current projects
No projects listed.